Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2005 September;24(3) > International Angiology 2005 September;24(3):304-7

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

INTERNATIONAL ANGIOLOGY

Rivista di Angiologia


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

CASE REPORTS  


International Angiology 2005 September;24(3):304-7

Copyright © 2005 EDIZIONI MINERVA MEDICA

lingua: Inglese

Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab

TATÒ F. 1, RIEGER J. 2, HOFFMANN U. 1

1 Department of Angiology, Ludwig-Maximilians-University of Munich, Munich, Germany 2 Department of Clinical Radiology, Ludwig-Maximilians-University of Munich, Munich, Germany


PDF  


Treatment of Takayasu’s arteritis remains a demanding challenge to clinicians. In many patients the course of the disease is characterized by frequent relapses and disease progression under conventional treatment with glucocorticoids and cytotoxic drugs. We present the case of a young woman with severe cerebrovascular and aortic involvement, who experienced disease progression in spite of more than 2 years of treatment with high doses of prednisone, methotrexate and cyclophosphamide. In this patient, treatment with the human, monoclonal anti-tumor necrosis factor-a (TNFa)-antibody adalimumab achieved clinical remission and allowed tapering of prednisone within a few months. The present case, as well as previous reports on the use of infliximab in giant cell and Takayasu’s arteries, suggests that TNFa-blockade may be a new, promising treatment for glucocorticoid-refractory large-vessel vasculitis.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail